Depo-Provera

Endometrial Hyperplasia, Endometriosis, Chronic Pain + 18 more
Treatment
7 FDA approvals
20 Active Studies for Depo-Provera

What is Depo-Provera

Medroxyprogesterone acetateThe Generic name of this drug
Treatment SummaryMedroxyprogesterone acetate (MPA) is a hormone-based drug that was approved by the FDA in 1959. Its main purpose is to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, and osteoporosis. It can also be used to reduce pain in endometriosis, manage vasomotor symptoms in menopause, and prevent pregnancy. MPA is also used to treat endometrial and renal carcinoma in palliative care.
Medroxyprogesterone Acetateis the brand name
image of different drug pills on a surface
Depo-Provera Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Medroxyprogesterone Acetate
Medroxyprogesterone acetate
1959
139

Approved as Treatment by the FDA

Medroxyprogesterone acetate, also known as Medroxyprogesterone Acetate, is approved by the FDA for 7 uses such as Vulvo Vaginal Atrophy and Postmenopausal Osteoporosis .
Vulvo Vaginal Atrophy
Used to treat Vulvo Vaginal Atrophy in combination with Conjugated estrogens
Postmenopausal Osteoporosis
Used to treat Postmenopausal Osteoporosis in combination with Conjugated estrogens
Vasomotor Symptoms Associated With Menopause
Used to treat Vasomotor Symptoms Associated With Menopause in combination with Conjugated estrogens
Hot flashes
Used to treat Menopause in combination with Conjugated estrogens
Hot Flashes
Used to treat Vasomotor Symptoms Associated With Menopause in combination with Conjugated estrogens
Osteoporosis, Postmenopausal
Used to treat Postmenopausal Osteoporosis in combination with Conjugated estrogens
Atrophic
Used to treat Vulvo Vaginal Atrophy in combination with Conjugated estrogens

Effectiveness

How Depo-Provera Affects PatientsMedroxyprogesterone acetate, or MPA, blocks hormones that help cells grow and can cause cell death in cancer cells. Depending on the form of MPA taken, its effects can last for up to a week. The drug is available in doses from 5mg daily to 1000mg a week, so it can be taken in a variety of ways. Unfortunately, long-term use of MPA can reduce bone density and lead to osteoporosis and fractures in the future - especially if taken during adolescence.
How Depo-Provera works in the bodyMedroxyprogesterone acetate (MPA) works to prevent pregnancy by stopping the release of hormones that cause ovulation. It also thins the lining of the uterus. MPA reduces estrogen receptors in the endometrium, and can induce apoptosis in some cancer cell lines. It also works to inhibit certain GABA-A receptors.

When to interrupt dosage

The prescribed dosage of Depo-Provera is contingent upon the diagnosed condition, for example Hormonal Contraception, Amenorrhea and Postmenopausal Osteoporosis. The level of dosage is contingent upon the mode of administration (e.g. Tablet - Oral or Intramuscular) stated in the table hereunder.
Condition
Dosage
Administration
Endometriosis
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
Chronic Pain
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
Amenorrhea
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
Osteoporosis
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
conjugated estrogen
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
hypoestrogenism
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
Birth Control
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
Endometriosis
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
Endometrial Neoplasms
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
Fracture
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
Hot flashes
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
Osteoporosis, Postmenopausal
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
Estrogen Replacement Therapy
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
Hot Flashes
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
Uterine hemorrhage
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
Atrophic
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
Hormonal Contraception
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
Kidney Neoplasms
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
Pharmaceutical Preparations
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral
Pharmaceutical Preparations
, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular, Injection, suspension - Intramuscular, Injection, suspension, Tablet, sugar coated, Tablet, sugar coated - Oral, Suspension, Suspension - Intramuscular, Kit; Tablet, Kit; Tablet - Oral, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection, Injection - Intramuscular, Kit - Oral

Warnings

Depo-Provera Contraindications
Condition
Risk Level
Notes
Thromboembolism
Do Not Combine
Breast
Do Not Combine
Thrombophlebitis
Do Not Combine
Neoplasms, Hormone-Dependent
Do Not Combine
Breast
Do Not Combine
Breast Cancer
Do Not Combine
Stroke
Do Not Combine
Vascular Diseases
Do Not Combine
Thromboembolism
Do Not Combine
Liver Disease
Do Not Combine
estrogen-dependent neoplasia
Do Not Combine
suspected pregnancy
Do Not Combine
Disease
Do Not Combine
undiagnosed abnormal genital bleeding
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Medroxyprogesterone Acetate may interact with Pulse Frequency
There are 20 known major drug interactions with Depo-Provera.
Common Depo-Provera Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be increased when combined with Medroxyprogesterone acetate.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Medroxyprogesterone acetate.
Alectinib
Major
The metabolism of Alectinib can be increased when combined with Medroxyprogesterone acetate.
Alpelisib
Major
The metabolism of Alpelisib can be increased when combined with Medroxyprogesterone acetate.
Aminophylline
Major
The metabolism of Aminophylline can be increased when combined with Medroxyprogesterone acetate.
Depo-Provera Toxicity & Overdose RiskThe lowest toxic dose of medroxyprogesterone acetate in rats is greater than 6400mg/kg and in mice is greater than 16g/kg. Overdosing on MPA can cause symptoms such as nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness, fatigue, and vaginal bleeding. If someone has been given too much of a MPA depo injection, they should seek medical help immediately.
image of a doctor in a lab doing drug, clinical research

Depo-Provera Novel Uses: Which Conditions Have a Clinical Trial Featuring Depo-Provera?

406 active clinical trials are currently assessing the potential of Depo-Provera to provide Osteoporosis, Amenorrhea and Hormonal Contraception relief.
Condition
Clinical Trials
Trial Phases
Endometriosis
27 Actively Recruiting
Early Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4
Osteoporosis
27 Actively Recruiting
Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2
Chronic Pain
129 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Phase 3, Early Phase 1, Phase 1
Endometrial Neoplasms
0 Actively Recruiting
Fracture
0 Actively Recruiting
Osteoporosis, Postmenopausal
0 Actively Recruiting
Pharmaceutical Preparations
0 Actively Recruiting
Birth Control
22 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2
Estrogen Replacement Therapy
0 Actively Recruiting
Hormonal Contraception
0 Actively Recruiting
Endometriosis
2 Actively Recruiting
Phase 4, Not Applicable
Hot Flashes
4 Actively Recruiting
Not Applicable, Phase 2, Phase 1
Kidney Neoplasms
34 Actively Recruiting
Phase 1, Phase 3, Phase 2, Not Applicable
conjugated estrogen
0 Actively Recruiting
Hot flashes
19 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3
hypoestrogenism
1 Actively Recruiting
Phase 4
Atrophic
3 Actively Recruiting
Phase 4, Not Applicable
Amenorrhea
0 Actively Recruiting
Pharmaceutical Preparations
0 Actively Recruiting
Endometrial Hyperplasia
4 Actively Recruiting
Not Applicable, Phase 2, Phase 3

Depo-Provera Reviews: What are patients saying about Depo-Provera?

5Patient Review
8/26/2022
Depo-Provera for Endometriosis
This shot took some time to work for me, but it was well worth the wait. I have endometriosis and had already undergone surgery when I started this treatment. The first three months were tough with pain, bleeding, and mood swings, but after getting the second shot things really improved. Everyone is different, but don't expect this medication to fix all your problems in a month. Give it some chance to work its magic!
5Patient Review
8/21/2022
Depo-Provera for Birth Control
I no longer have to deal with periods, which is amazing because they used to be really painful and heavy before I started this medication. They were affecting my iron levels as well, and since I already had anemia, I had to get four infusions of iron every week for weeks on end.
4.3Patient Review
6/20/2022
Depo-Provera for Endometriosis
I've started taking depo to help with the pain and heavy bleeding I experience during my period. So far, I'm really pleased with it. I haven't had any side effects or bleed through since starting it a few weeks ago. Fingers crossed that it continues to go well!
4.3Patient Review
9/24/2022
Depo-Provera for Birth Control
I've been on Depo-Provera for 11 years and, while there are some drawbacks like having to go to the doctor every 3 months and experiencing shakes, anxiety, heart palpitations, etc., I never have to worry about my period anymore. That being said, I am concerned about the bone loss that this is said to cause.
4Patient Review
10/31/2022
Depo-Provera for Birth Control
I started the depo shot in September of 2021, and I was on it for over a year. Unfortunately, during that time I experienced extremely heavy and painful periods. Additionally, my sex drive plummeted while I was on this medication. Thankfully, I've since switched to the pill which has been much better for me.
3Patient Review
10/17/2022
Depo-Provera for Birth Control
I gained a lot of weight while using this medication, but fortunately lost all of it after I stopped taking it. It was always very effective at preventing pregnancy, but the side effects were really terrible. I wouldn't recommend it to anyone.
2.7Patient Review
9/1/2022
Depo-Provera for Birth Control
I started the depo shot on April 21st and experienced spotting every day for the next three months. I'm now in September and still haven't gotten my period back. This birth control method really messed up my body.
2.3Patient Review
8/5/2022
Depo-Provera for Birth Control
I lost 20 pounds in 6 months while on the depo shot, but I started experiencing a whole host of other problems like PCOS, hair loss, anxiety, and depression. I stopped it a month ago and hope my health will improve.
2Patient Review
1/31/2022
Depo-Provera for Birth Control
I was on my period for almost three weeks straight, which finally stopped last night. It was an incredibly difficult and frustrating experience; I felt dizzy, bloated, had mood swings, and low self-esteem the entire time. I would never get this shot again.
1Patient Review
3/13/2022
Depo-Provera for Birth Control
I took the shot once and started experiencing weight gain, mood swings, and depression. My period also began about a week after taking it and I've been bleeding ever since--two periods a month, heavy and with daily spotting. If you're doubting whether or not to take this medication, trust your gut instinct.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about depo-provera

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Depo-Provera cause weight gain?

"Depot Provera (DMPA) is a commonly used and effective form of birth control, however, most studies confirm that weight gain is a common side effect for those who use it. DMPA is more likely to cause weight gain than other methods like the pill or an IUD."

Answered by AI

How long does Depo-Provera take to work?

"If you want to be protected from pregnancy as soon as possible, you should get your first birth control shot within the first 7 days after the start of your period. If you wait longer than that, it will take a full week for the shot to become effective. To be safe, you should use a backup method of contraception, like condoms, for the first week after getting the shot."

Answered by AI

What is the most common side effect of Depo-Provera?

"The shot can also make your periods lighter, heavier, or more frequent.

The birth control shot is most commonly associated with irregular bleeding. You may experience bleeding problems for 6 to 12 months after you first begin using the shot. The shot can also make your periods lighter, heavier, or more frequent."

Answered by AI

What does Depo do to your body?

"The Depo-Provera shot affects ovulation by preventing an egg from being released from a woman's ovary. It also thickens the cervical mucus, making it difficult for sperm to reach the egg."

Answered by AI

Clinical Trials for Depo-Provera

Image of Altasciences in Mount Royal, Canada.

Elinzanetant for Hot Flashes

18 - 65
Female
Mount Royal, Canada
The aim of this study is to examine the relative bioavailability of elinzanetant when administered in new oral formulations (treatment B and C) after both single and multiple oral doses, compared to its administration in soft gel capsule form (treatment A). Study details include: An ambulatory screening visit within 4 weeks prior to first treatment. Participants will be admitted to the ward on Day -1 of each period. On Day 1, either treatment B or treatment C will be administered fasted in the evening, followed by blood sampling for a 24-hour pharmacokinetic (PK) profile. On Day 2, the multiple dosing starts 3 hours after a standardized dinner in the evening. After the last dosing on Day 7, a complete PK profile for 24 hours will be collected. If there are no medical objections, participants will be discharged from the study ward on Day 9 in the morning for a washout-out period of at least 10 days (240 hours after last dosing, after period 1 and 2) or, in period 3, after the follow-up examination. The total duration of the study will be approximately 10 to 12 weeks for each participant.
Phase 1
Recruiting
AltasciencesBayer
Image of Vanderbilt University Medical Center in Nashville, United States.

Lidocaine Infusions for Postoperative Pain

18+
All Sexes
Nashville, TN
The goal of this single-center, pragmatic, randomized, blinded, placebo-controlled trial is to evaluate the impact of intravenous (IV) lidocaine within the existing Enhanced Recovery After Surgery (ERAS)program on outcomes in patients after major abdominal surgery. The main questions the trial aims to answer are: The primary hypothesis is that utilization of IV lidocaine as part of a perioperative multimodal pain regimen will result in a reduction in hospital Case Mix Index-Adjusted Resource Length of Stay (CARLOS). The secondary hypotheses are that lidocaine infusion will result in a reduction in total inpatient opioid consumption (oral morphine milligram equivalents, oMMEs) and pain scores, and improved surgical outcomes (including return of bowel function, ileus, nausea, rapid responses called, surgical site infections, and ICU transfers), while also having minimal incidence of side effects (including double/blurry vision, tinnitus, sedation, and adverse events requiring early cessation).
Phase 4
Waitlist Available
Vanderbilt University Medical CenterDanial Shams, MD
Have you considered Depo-Provera clinical trials? We made a collection of clinical trials featuring Depo-Provera, we think they might fit your search criteria.Go to Trials
Image of City of Hope Medical Center in Duarte, United States.

RP2 + Tivozanib for Kidney Cancer

18+
All Sexes
Duarte, CA
This phase II trial tests the effect of RP2 and tivozanib in treating patients with renal cell cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that is growing, spreading, or getting worse (progressive) after receiving immunotherapy with immune checkpoint inhibitors (ICIs). RP2 is a herpes simplex virus (a viral infection commonly known as the "cold sore virus") that has been changed to infect and destroy tumor cells and to activate (turn on) the human immune system to attack the tumor cells. Tivozanib hydrochloride blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Tivozanib hydrochloride is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Giving RP2 and tivozanib may be safe, tolerable, and/or effective in treating patients with metastatic renal cell cancer that has progressed after receiving immunotherapy with ICIs.
Phase 2
Waitlist Available
City of Hope Medical Center (+1 Sites)Charles B Nguyen
Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada
The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.
Phase 4
Recruiting
Erevna Innovations Inc.Andreas Nikolis, MD, PhD
Have you considered Depo-Provera clinical trials? We made a collection of clinical trials featuring Depo-Provera, we think they might fit your search criteria.Go to Trials
Image of University Hospitals Cleveland Medical Center in Cleveland, United States.

Ketamine for Pelvic Pain

18 - 89
Female
Cleveland, OH
The purpose of this research study is to see if ketamine infusion during surgery can decrease pain after surgery. Ketamine is a medication commonly used as part of anesthesia during surgery and is approved by the US FDA. Patients will be randomized to either receive standard anesthesia with OR without ketamine. The surgical procedure will be the same regardless of which group patients are randomized to. After surgery, patients will be asked to rate their pain in the post-operative observation unit and at their two-week post-operative visit. No additional visits are required for participation in this study. The investigators estimate the surveys will take approximately 10 minutes to complete.
Phase 4
Waitlist Available
University Hospitals Cleveland Medical CenterAdi Cosic, DO
Image of University Hospitals Cleveland Medical Center in Cleveland, United States.

Erector Spinae Plane Block for Pain

21 - 75
All Sexes
Cleveland, OH
As per usual care for spine surgery, participants will have their back cleaned with alcohol and a needle will be placed using ultrasound for the ESP block. Through the needle, a small catheter will be placed in the participants back and the needle removed. Approximately one hour prior to the start of surgery, a numbing medication (ropivacaine, similar to Novocaine) in combination with dexmedetomidine (a pain medicine that is used in nerve block and that is not a narcotic) and contrast dye (iohexol) will be injected through the catheter. Participants will then go through the QST procedure (test of buzzing sensation and temperature sensation through pads applied to their skin) to assess the numb areas and then head to the operating room. In the operating room, the catheter will be removed after the surgeon obtains baseline CT scan images of the spine. Once surgery is completed, investigators will record pain scores over the next four days in the hospital and the amount of pain medication needed for controlling pain related to the surgery.
Recruiting
Has No Placebo
University Hospitals Cleveland Medical CenterSalim Hayek, MD
Have you considered Depo-Provera clinical trials? We made a collection of clinical trials featuring Depo-Provera, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security